Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.

L. McGrath Gozde Kar L. Bonanno F. Guisier A. Insa M. Liberman O. Bylicki L. Livi T. Egenod Romain Corre Dong-Wan Kim M. Garcia Campelo M. Provencio Pulla Byoung Yong Shim G. Metro J. Bennouna Agata A. Bielska Alula R. Yohannes Joanna Shaju Yun He A. Dowson I. Grenga J. Spicer P. Forde T. Cascone
Oct 2026 · Nature · 0 citations
Medicine

TL;DR

Findings suggest combined assessment of ctDNA clearance and pCR may improve risk stratification, and that the numerically highest pCR4 and EFS rates with the Dato-DXd combination warrant further evaluation.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Sep 2026

Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET–CT-based study

Background Neoadjuvant chemoimmunotherapy is standard for resectable non-small-cell lung cancer (NSCLC) but response assessment is challenging due to pseudoprogression, which may lead to unnecessary cancellation of surgery. We characterized pseudoprogression and developed a clinical strategy to distinguish it from true...

Y. Pan, J. Chen, H. Lin et al. · 0 citations
Open access Oct 2026

Feasibility of consolidative immunotherapy and outcomes of chemoradiation for limited-stage small-cell lung cancer in the real world

Small-cell lung cancer (SCLC) is an aggressive disease presenting with limited stage (LS) in approximately 25% of cases. This study characterized the routine management of LS-SCLC as a benchmark for the advent of immune checkpoint inhibitors (ICI). A retrospective real-world cohort study of 533 consec...

Shuo Shi, Teresa Romero Cruz, Florian Stritzke et al. · 0 citations
Open access Oct 2026

Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer

Importance The I-SPY2.2 trial tests personalized treatment strategies to improve outcomes while reducing exposure to standard chemotherapy in patients with high-risk early breast cancer (EBC). Objective To evaluate the efficacy and safety of trastuzumab-deruxtecan (T-DXd), an antibody drug conjugate targeting low ERBB2...

C. O'Sullivan, K. Kalinsky, C. Yau et al. · 0 citations
Open access Oct 2026

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

The phase 2 MDT-BRIDGE study is investigating perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in resectable and borderline resectable non-small-cell lung cancer and chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen) in patients who become unresectable after neoadjuvan...

Martin Reck, E. Nadal, C. Gay et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.